New Pharmaceutics Study Findings Recently Were Reported by Researchers at Catholic University of Korea (In Vitro Metabolism and Transport Characteristics of Zastaprazan).

Researchers at the Catholic University of Korea have conducted a study on the drug Zastaprazan, a novel potassium-competitive acid blocker used for the treatment of erosive esophagitis. The study found that Zastaprazan is highly metabolized in human, mouse, and dog hepatocytes, but moderately metabolized in rat and monkey hepatocytes. The cytochrome P450 enzymes CYP3A4 and CYP3A5 were found to play major roles in the metabolism of Zastaprazan, while drug transporters had a minimal impact on the absorption, distribution, and excretion of the compound. These findings suggest that drug-metabolizing enzymes may have a significant role in determining the pharmacokinetics of Zastaprazan. [Extracted from the article]